Clinical Trials Logo

Acute Aortic Syndrome clinical trials

View clinical trials related to Acute Aortic Syndrome.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06277895 Recruiting - Clinical trials for Acute Coronary Syndrome

VOCs in Patients With Acute Cardiogenic Chest Pain

Start date: January 26, 2024
Phase: N/A
Study type: Interventional

The goal of this observation study is to compare VOCs in cardiogenic chest pain population/health conditions, to answer:Establishment and promotion of the application system of emergency rapid detection of expiratory Volatile Organic Compounds (VOCs) in patients with acute cardiogenic chest pain 1. VOCs levels were measured at baseline in healthy people, and markers of VOCs that could be used to identify acute cardiogenic chest pain were sought. 2. The relationship between abnormal VOCs (mainly aldehydes) and prognosis of patients and the correlation with Super-score for early warning of acute heart failure.

NCT ID: NCT05965453 Recruiting - Clinical trials for Acute Aortic Syndrome

Evaluation of the Castor Single Branch Stent Graft in Treatment of Acute Aortic Syndrome

ECAAS
Start date: June 1, 2018
Phase:
Study type: Observational

The objective of this study to evaluate the safety and effectiveness of the Castor single branch stent graft for endovascular repair of acute aortic syndrome patients without an inadequate proximal landing zone (<15mm)

NCT ID: NCT05339529 Recruiting - Clinical trials for Acute Aortic Syndrome

Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Thymosin α1) V

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with acute aortic syndrome (AAS). Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with thymosin alpha 1 may be beneficial. This study was designed to test the hypothesis that the administration of thymosin alpha 1 during the acute phase of AAS will result in a reduced incidence of SIRS and MODS.

NCT ID: NCT04699279 Recruiting - Clinical trials for Acute Aortic Syndrome

Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Rosuvastatin) I

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Acute Aortic Syndrome (AAS)/Aortic Aneurysm is a common feature of aortic wall events, including aortic dissection, intramural hematoma, aortic ulceration and aortic trauma, and occurs in up to 35 cases per 100,000 cases per year between the ages of 65 and 75 years. Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, the authors hypothesized that people with acute aortic syndrome but without hyperlipidemia might benefit from statin treatment.